한빛사논문
- 조회545
Sarah Nevins 1, Callan D McLoughlin 1, Alfredo Oliveros 2, Joshua B Stein 1, Mohammad Abdur Rashid 2, Yannan Hou 1, Mi-Hyeon Jang 2, Ki-Bum Lee 1
1Department of Chemistry and Chemical Biology, Rutgers University, the State University of New Jersey, 123 Bevier Road, Piscataway, NJ, 08854, USA.
2Department of Neurosurgery, Robert Wood Johnson Medical School, Rutgers University, the State University of New Jersey, 661 Hoes Ln W, Piscataway, NJ, 08854, USA.
CORRESPONDING AUTHORS: Mi-Hyeon Jang, Ki-Bum Lee
Abstract
Nanotechnology has emerged as a promising approach for the targeted delivery of therapeutic agents while improving their efficacy and safety. As a result, nanomaterial development for the selective targeting of cancers, with the possibility of treating off-target, detrimental sequelae caused by chemotherapy, is an important area of research. Breast and ovarian cancer are among the most common cancer types in women, and chemotherapy is an essential treatment modality for these diseases. However, chemotherapy-induced neurotoxicity, neuropathy, and cardiomyopathy are common side effects that can affect breast and ovarian cancer survivors quality of life. Therefore, there is an urgent need to develop effective prevention and treatment strategies for these adverse effects. Nanoparticles (NPs) have extreme potential for enhancing therapeutic efficacy but require continued research to elucidate beneficial interventions for women cancer survivors. In short, nanotechnology-based approaches have emerged as promising strategies for preventing and treating chemotherapy-induced neurotoxicity, neuropathy, and cardiomyopathy. NP-based drug delivery systems and therapeutics have shown potential for reducing the side effects of chemotherapeutics while improving drug efficacy. In this article, the latest nanotechnology approaches and their potential for the prevention and treatment of chemotherapy-induced neurotoxicity, neuropathy, and cardiomyopathy in breast and ovarian cancer survivors are discussed.
논문정보
- Review Paper
- 2023년 04월 (BRIC 등록일 2023-04-17)
- 국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
